"

"
. . .

/ & /

20 .
80
.

. 2006

.

(ADA, EASD 2012- 2013)

,
2
(, GLP-1, GLP-1, , )
,
3
.


, , .

, ,

.


.
:

,
7. DPP-4
GLP-1. DPP-4
, DPP-4

 . 12 (
) 94%
6% .

() 5
, ( HbA1c
0,6% ) ( ). 19
III.
22%
.

.
DPP-4

, ,
. SAVOR ( 2,2
placebo
). ( DPP-4)
,
, . DPP-4
.
GLP-1 2014
GLP-1 .
2-4h 4 5
GLP-1 ( GLP-1),
.
GLP-1, ,
0,7% - 1% HbA1c
1 3 kg.
GLP-1.
(exenatide LAR, byetta
) GLP-1
2014 .

( )
. DURATION
LAR
( 24 HbA1c 1,6% 0,9%
- byetta- 1,1% pioglitazone) ( 2,5
kg 1,3 kg byetta).
(13%),
.

.

 SGLT-2
, ,
SGLT-2.

- (SGLTs)
(
180gr. 0,8 gr.
24).
SGLTs


.
SGLTs. SGLT1
( S3 )
SGLT2
S1
. S1
90%
. SGLT2

(GLUT2) ,
.

SGLT2

.

SGLT-2
( , , )
(FDA EMEA)
SGLT-2.
(
) .
SGLT-2 (1200
SGLT-2 SGL1)
1-4h 12-17h.
HbA1c 0,9%
0,6% .

( 2-3kg)
( 4-5mmHg ).
( ) .
(O.R.

=1,4) ( 8-10% 3%
).

.


(basal
plus )
.
(glargine, detemir)
24,

.
degludec Lispro.
degludec
, FDA
. Glargine
Deglutec ,
( 43%) . Deglutec
( : 25,4h) (
8 40 )
.
Lispro
> 36h.

.

2013
,
,
DPP-4, GLP-1
(, ). ( )
(
GLP-1) (
HbA1c 0,5 0,8%),
,
.


, :
, (
GLP-1) .